Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-15), InventisBio Co's 14-Day RSI is 49.36.
The industry rank for InventisBio Co's 14-Day RSI or its related term are showing as below:
SHSE:688382's 14-Day RSI is ranked better than 56.1% of 1417
companies
in the Biotechnology industry
Industry Median: 51.69
vs SHSE:688382: 49.36
InventisBio Co (SHSE:688382) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
InventisBio Co 14-Day RSI Related Terms
SHSE:688382 vs VRTX, REGN, RVMD: 14-Day RSI Comparison
For the Biotechnology subindustry, InventisBio Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InventisBio Co 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InventisBio Co's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where InventisBio Co's 14-Day RSI falls into.
InventisBio Co (SHSE:688382) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InventisBio Co (SHSE:688382) has a 14-Day RSI of 49.36 as of Aug. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on InventisBio Co and its competitors. According to the industry distribution chart, InventisBio Co ranks #622 out of 1417 companies in the Biotechnology industry, placing it in the top 43.9%.
Is InventisBio Co's 14-Day RSI too high?
InventisBio Co's current 14-Day RSI is 49.36. The Biotechnology industry median 14-Day RSI is 51.69. InventisBio Co's value of 49.36 is 4.5% below this industry median. Based on the distribution chart, InventisBio Co ranks #622 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, InventisBio Co has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InventisBio Co's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InventisBio Co ranks #622 out of 1417 companies for 14-Day RSI. This puts InventisBio Co in the upper half of its industry. The industry median 14-Day RSI is 51.69. InventisBio Co's value of 49.36 is 4.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.69, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InventisBio Co's current 14-Day RSI of 49.36 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on InventisBio Co and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InventisBio Co's current 14-Day RSI is 49.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InventisBio Co stock overvalued right now?
Based on GuruFocus' analysis, InventisBio Co (SHSE:688382) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥10.07, compared to a current price of ¥21.09 — trading 109.4% above its estimated fair value. The current 14-Day RSI is 49.36 and 4.5% below the Biotechnology industry median of 51.69. InventisBio Co's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For InventisBio Co (SHSE:688382), the current 14-Day RSI is 49.36 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InventisBio Co (SHSE:688382) Overvalued in 2026?
Based on GuruFocus' analysis, InventisBio Co stock appears to be overvalued.
The current stock price of ¥21.09 is trading 109.4% above its estimated GF Value™ of ¥10.07.
GuruFocus considers InventisBio Co to be Significantly Overvalued.
Key valuation signals for SHSE:688382:
14-Day RSI: 49.36
GF Value™: ¥10.07 vs. price of ¥21.09 (109.4% above fair value)
Industry Position: 4.5% below the Biotechnology median (#622 of 1417)
No single metric tells the full story. See the SHSE:688382 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
43GF Score
Get the complete analysis for SHSE:688382
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688382 has been successfully added to your 
